Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Geisbert, Thomas W ^a   Feldmann, Heinz ^b,c,d  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EBOLA VACCINE; LIVE VACCINE; MARBURG VIRUS VACCINE; PROTEIN VP40; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS 5; ARTICLE; CELLULAR IMMUNITY; DRUG MEGADOSE; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; MARBURG HEMORRHAGIC FEVER; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS CELL INTERACTION; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MARBURG VIRUS DISEASE; MARBURGVIRUS; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL VACCINES;

EID: 80054741833     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir349     Document Type: Article

References (44)

1. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37. (Pubitemid 28527716)
2. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
3. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
4. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90. (Pubitemid 41021212)
5. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Crossprotection against Marburg virus strains using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-66. (Pubitemid 44435640)
6. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3: e177.
7. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88. (Pubitemid 46878044)
8. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196: S430-7. (Pubitemid 351417291)
9. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008; 26:6894-900.
10. Swenson DL, Wang D, Luo M, et al. Vaccine to confer complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008; 15:460-7. (Pubitemid 351967082)
11. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008; 7:417-29. (Pubitemid 351656813)
12. Geisbert TW, Geisbert JB, Leung A, et al. Single injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus. J Virol 2009; 83:7296-304.
13. Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOV GP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One 2009; 4:e5447.
14. Geisbert TW, Bailey M, Geisbert JB, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburgvirus in nonhuman primates. J Virol 2010; 84:10386-94.
15. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of crossprotective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 2010; 6:e1000904.
16. Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17: 572-81.
17. Feldmann H, Geisbert TW, Jahrling PB, et al. Filoviridae. In: Fauquet C, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus taxonomy: Eighth report of the International Committee on Taxonomy of Viruses. San Diego, CA: Elsevier/Academic Press, 2004; 645-53.
18. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola Viruses. In: Knipe DM, Howley PM, eds. Fields virology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006; 1409-48.
19. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:e1000212.
20. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995; 345:1271-4.
21. Rose JK, Schubert M. Rhabdovirus genomes and their products. In: Wagner RR, ed. The Rhabdoviruses. New York, NY: Plenum Publishing Corporation, 1987: 129-66.
22. Brandly CA, Hanson RP. Epizootiology of vesicular stomatitis. Am J Pub Health 1957; 47:205-9.
23. Johnson KM, Vogel JE, Peralta PH. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 1966; 15:244-6.
24. Brody JA, Fischer GF, Peralta PH. Vesicular stomatitis virus in Panama. Human serologic patterns in a cattle raising area. Am J Epidemiol 1967; 86:158-61.
25. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999; 73:3723-32. (Pubitemid 29189814)
26. Publicover J, Ramsburg E, Rose JK. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol 2004; 78:9317-24. (Pubitemid 39096541)
27. Clarke DK, Nasar F, Lee M, et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 2007; 81:2056-64. (Pubitemid 46214477)
28. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539-49. (Pubitemid 32879316)
29. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies virus from cloned cDNA. EMBO J 1994; 13:4195-203. (Pubitemid 24295191)
30. McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, Schnell MJ. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 2001; 75:4430-4. (Pubitemid 32410158)
31. McGettigan JP, Sarma S, Orenstein JM, Pomerantz RJ, Schnell MJ. Expression and immunogenicity of human immunodeficiency virus type 1 gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 2001; 75:8724-32. (Pubitemid 32768976)
32. Siler CA, McGettigan JP, Dietzcshold B, et al. Live and killed rhabdovirus- based vectors as potential hepatitis C vaccines. Virology 2002; 292:24-34. (Pubitemid 34925835)
33. Kretzschmar E, Buonocore L, Schnell MJ, Rose JK. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 1997; 71:5982-9. (Pubitemid 27304935)
34. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 1995; 92:4477-81.
35. Roberts A, Kretzschmar E, Perkins AS, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998; 72:4704-11. (Pubitemid 28215645)
36. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 1996; 93:11359-65. (Pubitemid 26347126)
37. Robain O, Chany-Fournier F, Cerutti I, Màzlo M, Chany C. Role of VSV G antigen in the development of experimental spongiform encephalopathy in mice. Acta Neuropathol 1986; 70:220-6. (Pubitemid 16046820)
38. van den Pol AN, Dalton KP, Rose JK. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 2002; 76:1309-27. (Pubitemid 34066434)
39. Martinez I, Rodriguez LL, Jimenez C, Pauszek SJ, Wertz GW. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol 2003; 77:8039-47. (Pubitemid 36792800)
40. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
41. Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007; 196:S404-12. (Pubitemid 351417288)
42. Daddario-DiCaprio KM, Geisbert TW, Ströher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment. Lancet 2006; 367:1399-404.
43. Feldmann H, Jones SM, Daddario-Dicaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
44. Geisbert TW, Daddario-Dicaprio KM, Williams K, et al. Recombinant vesicular stomatitis virus vector mediates post-exposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8. (Pubitemid 351705275)